DelveInsight’s Indication Pipeline Reports

Malignant Pleural Mesothelioma Upcoming Therapies

Business Consultant, DelveInsight's Drug Report, DelveInsight's Indication Pipeline Reports, DelveInsight's Oncology based Reports, Pharma Consultant, Snippets

Malignant pleural mesothelioma treatment market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and...

Read More

Malignant pleural mesothelioma market: Elusive treatment approaches and Poor diagnosis

Articles, Business Consultant, DelveInsight's Drug Report, DelveInsight's Indication Pipeline Reports, Pharma Consultant • One Comment

Malignant pleural mesothelioma (MPM) is a malignancy of pleural layers within the lung cavity and inner sides of the ribs.  Year of...

Read More

Egg Allergy Market: Second most common food allergy but no approved therapy

Articles, Business Consultant, DelveInsight's Drug Report, DelveInsight's Indication Pipeline Reports, Pharma Consultant

Hen’s egg allergy is the second most common type of allergy after cow’s milk. In infants and young children, Egg poses as one of the...

Read More

Chronic Hand Eczema Market

Articles, Business Consultant, DelveInsight's Drug Report, DelveInsight's Indication Pipeline Reports, Pharma Consultant

Eczema is an umbrella term comprising skin disorders characterised by dry, discoloured, itchy and inflamed skin. Hand eczema (HE) are...

Read More

Reversing Ischemia with Gene therapy

Articles, Business Consultant, DelveInsight's Indication Pipeline Reports, Gene Therapy Products, Pharma Consultant, Venous Thromboembolism

A human body comprises of many small, long, narrow and broad blood vessels that carry oxygenated blood from the heart to other body parts...

Read More

GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3

Articles, Business Consultant, DelveInsight's Indication Pipeline Reports, Notizia, Pharma Consultant, The Business Cocktail

Global Therapeutics and Syros Pharmaceuticals have teamed up to move forward to discover, develop and market novel Sickle cell disease and...

Read More
Close